Please try another search
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases in the United States. It develops ABI-5366 and ABI-1179, which is in Phase 1a/1b clinical trial targeting recurrent genital herpes; and ABI-6250, an oral hepatitis delta virus entry inhibitor that is in Phase 1a clinical studies. The company also offers ABI-4334, a next-generation capsid assembly modulator which is in Phase 1b clinical trials, for the treatment of hepatitis B virus. In addition, it provides an oral non-nucleoside polymerase inhibitor indicated for transplant-associated herpesviruses; and small molecule interferon-a receptor to treat hepatitis B and delta virus. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. It also has license agreement with Indiana University Research and Technology Corporation to develop and commercialize products for its HBV programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Antonio Bertoletti | - | 2020 | Member of Scientific Advisory Board |
Patrick Kennedy | - | 2020 | Member of Scientific Advisory Board |
Tomas Cihlar | - | 2023 | Director |
Anthony E. Altig | 68 | 2012 | Independent Director |
Adam Zlotnick | - | 2014 | Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board |
William R. Ringo | 79 | 2014 | Independent Non-Executive Chairman |
Lisa R. Johnson-Pratt | 60 | 2021 | Independent Director |
Michael Houghton | 73 | 2021 | Member of Scientific Advisory Board & Independent Director |
Stephan Urban | - | 2020 | Member of Scientific Advisory Board |
Jason A. Okazaki | 48 | 2020 | CEO, President & Director |
Robert Donald Cook | 65 | 2024 | Director |
Gina R. Consylman | 51 | 2020 | Independent Director |
John G. McHutchison | 66 | 2019 | Director |
Tomas Cihlar | 57 | 2023 | Director |
Susan M. Mahony | 60 | 2017 | Independent Director |
Alex Thompson | - | 2020 | Member of Scientific Advisory Board |
Edward J. Gane | - | 2020 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review